Ophthotech
One Penn Plaza
Suite 1924
New York
New York
10119
United States
Tel: 212-845-8200
Fax: 212-845-8250
Website: http://www.ophthotech.com/
About Ophthotech
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients.
128 articles about Ophthotech
-
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors
1/16/2018
Ophthotech announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.
-
Ophthotech Reports Third Quarter 2017 Financial and Operating Results
11/8/2017
As of September 30, 2017, the Company had $180.2 million in cash and cash equivalents.
-
Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
10/30/2017
Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a business update.
-
Ophthotech Provides Update On Zimura Complement Programs For Treatment Of Eye Diseases
9/19/2017
-
Ophthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study
8/15/2017
-
Ophthotech Reports Second Quarter 2017 Financial And Operating Results
7/26/2017
-
Ophthotech Expands Focus With Development For Ophthalmic Orphan Diseases
7/26/2017
-
Ophthotech To Report Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, July 26, 2017
7/21/2017
-
Ophthotech Reports First Quarter 2017 Financial And Operating Results
5/3/2017
-
Ophthotech To Report First Quarter 2017 Financial Results And Host Conference Call On Wednesday, May 3, 2017
4/26/2017
-
Ophthotech Co-Founder and CEO to Step Down, CFO Named New Leader
4/25/2017
-
Ophthotech Reports Fourth Quarter And Full Year 2016 Financial And Operating Results
2/28/2017
-
Ophthotech To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On Tuesday, February 28, 2017
2/22/2017
-
Struggling to Keep Its Head Above Water: Ophthotech to Review Strategic Alternatives and Shake Up C-Suite
2/1/2017
-
Battered Ophthotech Cuts 80% of Staff After Failed Clinical Trials
1/18/2017
-
Ophthotech Clinical Disaster Spurs Massive Layoffs
12/27/2016
-
Ophthotech Plunges as Wet AMD Drug Combo Trials With Novartis AG Flops in Phase III Studies
12/13/2016
-
Ophthotech Announces Results From Pivotal Phase 3 Trials Of Fovista In Wet Age-Related Macular Degeneration
12/12/2016
-
Ophthotech Reports Third Quarter 2016 Financial And Operating Results
11/8/2016
-
Ophthotech Announces The Publication Of Fovista In Combination With Lucentis Phase 2b Study Results In Ophthalmology, The Journal Of The American Academy of Ophthalmology
10/31/2016